GNF6702

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

GNF6702 is a broad‑spectrum antiprotozoal drug discovered in 2013 by researchers at the Genomics Institute of the Novartis Research Foundation. It targets three related diseases caused by kinetoplastid parasites: leishmaniasis, Chagas disease, and sleeping sickness. The compound works by inhibiting the parasite’s proteasome in an allosteric manner, disrupting protein recycling and stopping parasite growth. In mouse studies, GNF6702 was effective against infections from all three diseases and showed little toxicity to mammalian cells. Today it is mainly a research compound and not an approved medicine.